July 9, 2021
The admonition to the Institute for Clinical and Economic Review’s Beacon Hill economists should be quite simple: “Stay in your lane.”
July 8, 2021
Health plans are quietly cutting more and more medications from their list of approved drugs, narrowing patients’ treatment options.
May 11, 2021
The heartbreaking headline said it all: a new CAR-T personalized cancer treatment was found “effective, but too costly” by the economists at the Institute for Clinical and Economic Research.
March 3, 2021
Preventing a serious cardiac event is a top priority for my patients, but the Institute for Clinical and Economic Review is about to make prevention a whole lot harder.
January 7, 2021
When it comes to incorporating patients into decisions about medication and value, the United States just isn’t making the grade.
December 15, 2020
When you or someone you love has a cardiovascular event, life gets real – fast.
December 10, 2020
Effective treatments that reduce the risk factors associated with ASCVD offers tremendous value to the patient community. Read the Letter
November 2, 2020
Open enrollment comes at a busy time of year, so it can be tempting to rush through the process.
October 9, 2019
The controversial Institute for Clinical and Economic Review has done something unprecedented: admitted it’s wrong.
August 20, 2019
Medicare beneficiaries nationwide will soon have coverage for cutting-edge CAR-T cancer therapy, the Centers for Medicare and Medicaid Services announced this month.